Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 5/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.42 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3272263 | 0.85 | KDM4E (0.50) | BCHECHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL3581270 | 0.85 | BCHE (0.52) | BCHECHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL9957662 | 0.84 | CNR1 (0.49) | BCHECHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL5175871 | 0.82 | BCHE (0.49) | BCHECHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL3584103 | 0.82 | KDM4E (0.47) | BCHECHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL3386391 | 0.81 | ROCK1 (0.60) | KDM4EMEN1KMT2ACNR1SCN8A | |
| SCHEMBL3917296 | 0.81 | ROCK1 (0.60) | KDM4EMEN1KMT2ACNR1SCN8A | |
| SCHEMBL5176588 | 0.81 | CNR1 (0.46) | BCHECHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL5227133 | 0.80 | CETP (0.50) | BCHECHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL3391028 | 0.79 | TRPV1 (0.65) | CNR1RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101378763-B | Trialkylsilylbenzylaminocarboxyindoles, indazoles and indolines and their use in treating CETP-mediated disorders | HOFFMANN LA ROCHE | 2013-05-22 | — | — | CN | claimed |
| CN-101378763-B | Trialkylsilylbenzylaminocarboxyindoles, indazoles and indolines and their use in treating CETP-mediated disorders | HOFFMANN LA ROCHE | 2013-05-22 | — | — | CN | disclosed |
| EP-1984322-B1 | BENZAMIDE AND HETEROARENE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-09-26 | — | — | EP | disclosed |
| EP-1984002-B1 | TRIALKYLSILYLBENZYLAMINOCARBOXYINDOLES, INDAZOLES AND INDOLINES AND THEIR USE IN TREATING CETP-MEDIATED DISORDERS | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| US-7572823-B2 | Heteroaryl carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2009-08-11 | — | — | US | disclosed |
| CN-101378763-A | Trialkylsilylbenzylaminocarboxyindoles, indazoles and indolines and their use in treating CETP-mediated disorders | HOFFMANN LA ROCHE (CH) | 2009-03-04 | — | — | CN | disclosed |
| EP-1984002-A1 | TRIALKYLSILYLBENZYLAMINOCARBOXYINDOLES, INDAZOLES AND INDOLINES AND THEIR USE IN TREATING CETP-MEDIATED DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007090750-A1 | TRIALKYLSILYLBENZYLAMINOCARBOXYINDOLES, INDAZOLES AND INDOLINES AND THEIR USE IN TREATING CETP-MEDIATED DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185182-A1 | Heteroaryl carboxamide compounds | HOFFMAN-LA ROCHE INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185182-A1 | Heteroaryl carboxamide compounds | ABCB1, ABCG2, CYP3A43 | BCHE 2463/4885CHRM2 768/4885CHRM1 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.